37 completed. 37 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 37 | Completed 37 |
| Phase 2 | 1 | Completed 1 |
Follow Aprepitant: new trials by email Literature Review of Aprepitant trials Research Report on Aprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients Aprepitant 40mg, Placebo - Nausea and Vomiting, Postoperative, Prevention | Phase 3 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 260 | 2026-02-27 | 2026-08-27 |
| Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients Aprepitant Injection - Gynecological Tumor, Ovarian Cancer | Phase 3 | Completed | Sichuan Cancer Hospital and Research Institute | 143 | 2024-05-31 | 2025-12-04 |
| Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea Ibuprofen and Aprepitant - Primary Dysmenorrhea | Phase 3 | Completed | Lahore Medical Research Center, LLP | 40 | 2024-03-15 | 2025-02-21 |
| Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting Aprepitant Injection, Aprepitant Injection Placebo - Postoperative Nausea and Vomiting | Phase 3 | Completed | Qilu Pharmaceutical (Hainan) Co., Ltd. | 518 | 2024-02-02 | 2025-04-23 |
| Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine - Perioperative Optimization | Phase 3 | Completed | Jennifer Holder-Murray | 3395 | 2023-05-15 | 2026-05-28 |
| Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy Zyprexa® (OLANZapine 5MG), Emend® (Aprepitant) - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | CR-CSSS Champlain-Charles-Le Moyne | 30 | 2019-04-29 | 2020-08-19 |
| Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms Aprepitant 80 mg, Hydroxyzine 25mg, Placebo of Hydroxyzine - Myeloproliferative Disorder, Aquagenic Pruritus | Phase 3 | Completed | University Hospital, Brest | 63 | 2019-04-16 | 2025-12-03 |
| Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1, Olanzapine10 mg orally daily on Days -1,0,+1 and +2, Aprepitant plus Olanzapine - Nausea, Vomiting | Phase 3 | Completed | Rush University Medical Center | 52 | 2017-09-23 | 2024-10-22 |
| "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)" Ondansetron, Dexamethasone, Aprepitant - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | All India Institute of Medical Sciences | 240 | 2017-07-01 | 2019-08-20 |
| Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy Aprepitant, Palonosetron, Dexamethasone - Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Sun Yat-sen University | 248 | 2015-08-04 | 2023-02-08 |
| Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries dexamethasone, Gabapentin, Aprepitant - Postoperative Nausea and Vomiting | Phase 2 / Phase 3 | Completed | Assiut University | 150 | 2015-08-01 | 2016-03-24 |
| Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting Olanzapine, Aprepitant, Palonosetron - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | First Affiliated Hospital of Harbin Medical University | 120 | 2015-05-01 | 2017-03-30 |
| Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis Aprepitant, Mirtazapine - Breast Cancer | Phase 3 | Completed | Fudan University | 212 | 2014-12-01 | 2022-04-20 |
| Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant) - Hematopoietic/Lymphoid Cancer, Nausea and Vomiting | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 401 | 2014-08-20 | 2025-01-28 |
| Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers Aprepitant, placebo - Carcinoma, Non-small Cell Lung | Phase 3 | Completed | Hunan Province Tumor Hospital | 244 | 2014-02-01 | 2020-03-26 |
| Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) Fosaprepitant dimeglumine, Fosaprepitant Placebo, Dexamethasone - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1015 | 2012-09-24 | 2018-09-04 |
| Efficacy of Aprepitant (Emend®) in Children Ondansetron, dexamethasone, aprepitant, Ondansetron, Dexamethasone, placebo - Nausea, Vomiting | Phase 3 | Completed | University of Oklahoma | 19 | 2012-06-01 | 2021-03-23 |
| A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS) - Chemotherapy Induced Nausea and Vomiting | Phase 3 | Completed | Merck Sharp & Dohme LLC | 307 | 2011-09-13 | 2018-09-25 |
| Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy Aprepitant, Placebo - Chemotherapy Induced Nausea and Vomiting | Phase 3 | Completed | All India Institute of Medical Sciences | 96 | 2011-08-01 | 2015-01-19 |
| A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting Netupitant and Palonosetron, Aprepitant, Palonosetron - Chemotherapy-Induced Nausea and Vomiting | Phase 3 | Completed | Helsinn Healthcare SA | 413 | 2011-07-01 | 2014-11-17 |
Showing 20 of 37. Sign in to see all of them.
Vomiting (17) · Depressive Disorder, Major (9) · Postoperative Nausea and Vomiting (6) · Nausea (5) · Breast Neoplasms (3) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Hematologic Neoplasms (1) · Inflammatory Breast Neoplasms (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms, Germ Cell and Embryonal (1)
Merck Sharp & Dohme LLC (17) · All India Institute of Medical Sciences (2) · Alliance for Clinical Trials in Oncology (1) · Assiut University (1) · CR-CSSS Champlain-Charles-Le Moyne (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · First Affiliated Hospital of Harbin Medical University (1) · Fudan University (1) · Helsinn Healthcare SA (1) · Hoosier Cancer Research Network (1) · Hunan Province Tumor Hospital (1) · Jennifer Holder-Murray (1) · Joseph Roscoe (1) · Lahore Medical Research Center, LLP (1) · Qilu Pharmaceutical (Hainan) Co., Ltd. (1)
United States (7) · China (6) · India (3) · Canada (2) · Bulgaria (1) · Czechia (1) · Egypt (1) · France (1) · Germany (1) · Hungary (1) · Pakistan (1) · Poland (1) · Russia (1) · Serbia (1) · Ukraine (1)
Catherine Prady, Md (1) · Daxin Zhang, MD (1) · Hala S Abdel-Ghaffar, MD (1) · Joseph A. Roscoe, PhD (1) · Kathryn Schultz, PharmD (1) · Lawrence Einhorn, M.D. (1) · Maxim Roy, MD, FRCPC (1) · Nong Yang, MD (1) · Rene McNall-Knapp, MD (1) · Rudolph M. Navari, MD, PhD, FACP (1) · Sameer Bakhshi, MD (1) · Stephen Esper, MD, MBA (1)
PMID 16248986, PMID 23062719, PMID 11030465, PMID 12736106, PMID 19568773, PMID 19775450, PMID 22024310, PMID 22141732, PMID 22915652, PMID 22915657, PMID 23598819, PMID 24276953, PMID 24911369, PMID 25770814, PMID 26449391, PMID 27410922, PMID 28285236, PMID 29808377, PMID 29893452, PMID 30373688, PMID 30968588, PMID 32036491, PMID 32931400, PMID 32988373, PMID 33835174, PMID 34923994, PMID 38154902, PMID 8232489
2018 (1), U10CA031946 (1), U10CA037420 (1)